Blume Capital Management, Inc. Cara Therapeutics, Inc. Transaction History
Blume Capital Management, Inc.
- $401 Million
- Q1 2024
Shares
2 transactions
Others Institutions Holding CARA
# of Institutions
102Shares Held
21.5MCall Options Held
50KPut Options Held
0-
Black Rock Inc. New York, NY3.42MShares$889,5540.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.48MShares$645,1270.0% of portfolio
-
Disciplined Growth Investors Inc Minneapolis, MN1.82MShares$471,9150.03% of portfolio
-
Chescapmanager LLC Baltimore, MD1.7MShares$442,5480.15% of portfolio
-
Farallon Capital Management LLC San Francisco, CA1.56MShares$404,6250.01% of portfolio
About Cara Therapeutics, Inc.
- Ticker CARA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,725,900
- Market Cap $14M
- Description
- Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...